The pilot bioavailability study comparing the absorption of carbetocin (which is used as prevention of heavy bleeding after childbirth) in PABAL 100 μg/mL Solution for Injection when administered sublingually in the dose of 500 μg and intramuscularly in the dose of 100 μg.

This research study is focused on a medicine called carbetocin. Carbetocin is an important treatment used to help prevent heavy bleeding that can happen after a woman gives birth. This heavy bleeding, called postpartum haemorrhage, can be very serious, so finding the best way to give medicines like carbetocin is really important.

The main goal of this particular study is to understand how carbetocin gets into the body when it's given in two different ways. One way is a small injection into a muscle, a common way to give medicines. The other way is to give a slightly larger dose as a liquid under the tongue, which might be a more convenient option in some situations. By comparing these two methods, scientists can see which way helps the medicine get into the bloodstream most effectively and quickly.

This type of research is called a "bioavailability" study. It’s an early step in developing medicines and typically doesn't involve patients with a specific illness. Instead, it helps researchers learn the nuts and bolts of how a drug behaves in the body. The information gathered from this study will help doctors and pharmaceutical companies decide the best way to give carbetocin to women who need it after childbirth.